News

CanPharma News Feed

No more posts
crohns_disease-1200x900.jpg
13/Sep/2019

The association of cannabis with the reduction of developmental colorectal cancer

Case studies suggest that there is an anti-inflammatory agent in cannabis. 

One study found a link between cannabis use and a lower risk of colon cancer, anaemia and hospitalisation.

The nationwide inpatient sample data sets (2010-2014) were examined to identify adults with crohn’s disease (CD) and ulcerative colitis (UC). 

Recent studies about Crohn’s disease and Cannabis

This is the result of a study conducted by Atlanta VA Medical Center in Decatur, USA:

The study examined 6,002 patients  with CD (2,999 cannabis users & 3,003 non-users) and 1,481 patients with UC (742 cannabis users & 739 non-users). 

In patients with CD, the presence of colorectal cancer, the need for parenteral nutrition, and anemia were lower in cannabis users. 

However, active fistula disease or intra-abdominal abscess formation, non-specific bleeding in the lower gastrointestinal tract and hypovolemia were higher in recreational cannabis use. 

Additionally, the average hospital stay was shorter with lower hospital costs among cannabis users.

 

Source: Cannabis-med

Image: AGMG


Schizophrenia.jpg
11/Sep/2019

According to a study published in 2017 by the American Journal of Psychiatry, researchers have come to a conclusion that CBD can have a positive effect in patients with schizophrenia.

Studies about medical cannabis efficacy for Schizophrenia

The aim of this study was to investigate the safety and efficacy of CBD as an accompanying therapy for schizophrenia.  In a randomized (1:1 ratio) and double-blinded study, patients received either CBD (1000mg/day; N=43) or a placebo (N=45) as additional therapy to their existing antipsychotic medication for 6 weeks. Participants were assessed for effects of CBD before and after the treatment using the positive and negative Syndrom scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).According to the study, the CBD group, compared to the placebo group, showed improvements in cognitive performance, functional range, and overall clinical impression of the patient. 

These results suggest that CBD may be a possible alternative in the treatment of schizophrenia.

Source: https://www.ncbi.nlm.nih.gov/pubmed/29241357


opioids-vs-cannabis.jpg
05/Sep/2019

According to a study, patients repeatedly reported that cannabis is used as a substitute for prescription drugs, but little is known about people who legally purchase cannabis through the adult cannabis market. 

The study was conducted in 2016 in Colorado, United States, in which 1000 adults were interviewed about their use of (medical) cannabis, 65% of respondents reported that they used cannabis to relieve their pain and 74% said they used cannabis to promote sleep. All respondents who reported medical certification were excluded. 

Among those who took cannabis to sleep, 84% found it very helpful, and those who took over-the-counter medicines (87%) or prescription sleeping pills (83%) said they either reduced their use or stopped using them completely. 

This suggests that medical use of cannabis is common where cannabis is legally available and also reduces drug use. Laws for adult cannabis use could increase access to cannabis to treat illnesses.

Source:

https://www.cannabis-med.org/


liver2.jpg
30/Aug/2019

The increased development of obesity and excess weight can lead to non-alcoholic fatty liver diseases. Recent findings suggest that cannabis use has a protective effect on weight gain and associated metabolic changes in  patients with psychosis.

According to a three year longitudinal study published in 2019, cannabis use can have a protective effect against liver steatosis.

390 patients were examined at two points in time.  Firstly, at the start of the study, and secondly, after 3 years of initiating antipsychotic treatment. Anthropometric measurements and liver, lipid, and glycemic parameters were obtained at both points in time. Patients were treated at the Department of Psychiatry of the University Hospital de Valdecilla in Santander, Spain. 

During the second examination, cannabis users significantly had lower FLI (Fatty Liver Index) values than non-users.

In addition, cannabis users met the criteria for liver steatosis less frequently than non-users. Patients who consistently used cannabis after 3 years of use represented the smallest increase in FLI over time. 

Source:Cannabis-Med


CBD-OMS-1200x800.png
28/Aug/2019

Research shows that CBD can be used to decrease the frequency of seizures without the psychoactive properties of medical cannabis.

The World Health Organisation (WHO) announced that there medicinal and therapeutic benefits of cannabidiol (CBD) and one of the pathologies which can be treated is epilepsy.

Epilepsy is when two or more unprovoked and unexpected seizures arise. Seizures are brief episodes of involuntary movement that may involve the entire body (generalized) or a part of the body (partial).

Medically, refractory epilepsy remains an area of scientific interest as up to 35% of patients continue to suffer from seizures despite current therapies. Recent evidence has focused on the benefit of cannabidiol (CBD), a marijuana plant-based product with no psychoactive properties, can be used to decrease seizure frequency.

Medical Research with Oral CBD

In 2019, a group of researchers analysed several published articles of this pure oral CBD extract as an additional therapy for treating refractory epilepsy, Lennox-Gastaut and Dravet syndromes, convulsive seizures decrease by 50%. Additionally, in patients with treatment-resistant epilepsy of multiple aetiologies, similar benefits were observed.

Furthermore, a stopped/decreased dose of anti-seizure medication was observed when taking the CBD oil.

The therapeutic potential of CBD in epilepsy exists, however, further studies are still needed to better understand the full mechanism of action.

Source:

https://www.kalapa-clinic.com/en/new-stance-cbd-who/

 


OCD-cannabinoides.png
23/Aug/2019

The Obsessive-compulsive disorder(OCD) is a mental disorder marked by anxiety or distress, characterized by the presence of persistent thoughts (better known as obsessions). These recurrent thoughts are suppressed by new ones or actions, known as compulsions (acts performed in response to the obsession). The compulsions aim at preventing the anxiety or distress.

Around 60% of patients with Obsessive-Compulsive Disorder do not respond to first-line treatment. Options in these cases include an increase of dosages or switching to another drug. In this sense, new evidence reported patients with treatment-resistant OCD who could respond better to an increase dosage of medications combined with medical cannabis.

Clinical studies confirm effective results using cannabinoids in patients with OCD

In 2008, researchers published an article in the American Journal of Psychiatry. In this article, the researchers presented the experiences of two refractory OCD patients after synthetic THC administration.

To the female subject, doctors had prescribed for 8 months an antidepressant and psychological therapy to treat her OCD and major depression, but without success. Interestingly, the woman reported that when she smoked cannabis, her symptoms were relieved. It was then decided to supplement her current treatment with synthetic THC. Her OCD symptoms were reduced, and her severity disease score improved by 50%. Regarding the male subject, after the addition of the synthetic THC to the ongoing medication, his symptoms were reduced within 2 weeks, and his severity disease score improved by 35%.

In 2010, a clinical study was subsequently published in the Journal Behavioral Pharmacology, describing the observation of CBD effects on rodents. In this study, the researchers found that Cannabidiol (CBD) has been shown to have anxiolytic effects, both in animals and humans, could significantly reduce symptoms associated with stimulated compulsive animal behavior.

In general, these studies demonstrated a therapeutic potential of cannabinoids to reduce Refractory obsessive compulsive disorders. However, new studies are needed to definitively validate its utility or not.

Source:

https://www.kalapa-clinic.com/en/refractory-obsessive-compulsive-disorder/


chronic-pain-medical-cannabis-investigation.jpg
21/Aug/2019

Chronic pain (CP) is a long-lasting unpleasant sensorial and emotional experience without the acute warning signals of physiological nociception that persists past normal healing time and usually lasts or recurs for more than 3 months. It is a common and economically important health issue, affecting approximately 20% of people worldwide and accounting accordingly for 15-20% of medical consultations.

According to an exploratory analysis of anonymized 12-week open-label data provided by the German Pain e-Registry add-on treatment with the cannabis spray Sativex was effective and well-tolerated. Data were analyzed by scientists of the Institute of Neurological Sciences in Nuremberg, Germany, and other German institutions.
Among that 30.228 cases documented in the database in 2017, 800 (2.6%) received a treatment with Sativex containing THC and CBD in a ratio of about 1:1. Authors found a significant treatment effect.

Beneficial effects using CBD:THC oromucosal spray

Authors concluded that the Beneficial effects found for CP patients in this analysis clearly out weighted the potential risks of treatments and confirmed that THC:CBD oromucosal spray provides an effective add-on measure for patients suffering either from elsewhere refractory neuropathic pain conditions as well as those presenting with a pain phenotype suggestive for underlying neuropathic mechanisms.

Source:

Journal of Pain Research : Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain


Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.

MEMBER OF

footerlogos

OFFICES

CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg
Germany

IberCanPharma LDA
Rua João Fernandes
Lavrador 1 – Sala 6 2825-
132 Vila Nova de Caparica
Portugal

REPRESENTATIVE OFFICES

Berlin
Neue Kantstraße 18
14057 Berlin
Germany

Barcelona
Gran de Gràcia 15, 1-1
08012 Barcelona
Spain